Clinical trial
Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing…
NCT00119379 · National Institute of Allergy and Infectious Diseases (NIAID), NIH · Completed
Key facts
| NCT number | NCT00119379 |
|---|---|
| Title | Effectiveness of Nucleoside Supplementation or Switch to Tenofovir in Reversing Fat Loss in HIV Infected Adults |
| Official title | Reversibility of Mitochondrial Toxicity in HIV Lipoatrophy |
| Lead sponsor | National Institute of Allergy and Infectious Diseases (NIAID), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | HIV Infections, Lipodystrophy, Metabolic Diseases, Nutrition Disorders |
| Intervention type | Drug |
| Interventions | NucleomaxX, Tenofovir Disoproxil Fumarate |
| Enrollment | 50 |
| Start date | Apr 1, 2005 |
| Primary completion | Oct 1, 2008 |
| Completion | Oct 1, 2008 |
| First posted | Jul 13, 2005 |
| Last update posted | Jun 7, 2017 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: